Our previous research for the first time found that compared with CD34+ cells from cord blood, healthy mobilization and non-treated CML patients, CD34+ cells in CML patients treated with TKI presented more senescence phenotypes. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.